Daiichi Sankyo Company, Limited (4568.T)
| Previous close | 4,536.00 |
| Open | 4,535.00 |
| Bid | 4,635.00 x N/A |
| Ask | 4,640.00 x N/A |
| Day's range | 4,521.00 - 4,642.00 |
| 52-week range | 3,566.00 - 5,173.00 |
| Volume | |
| Avg. volume | 4,065,793 |
| Market cap | 8.889T |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 47.76 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 60.00 (1.32%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
- Business Wire
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors
- Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
- Business Wire
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
TOKYO & BASKING RIDGE, N.J., April 02, 2024--Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease.
